Effectiveness and Safety of Platelet Rich Plasma (PRP) on Persistent Olfactory Dysfunction Related to COVID-19

Centre Hospitalier Universitaire Saint Pierre

Status and phase

Completed

Phase 3

Phase 2

Conditions

COVID-19

Anosmia

Treatments

Other: olfactory training

Drug: Platelet rich plasma (PRP)

Study type

Interventional

Funder types

Other

Identifiers

NCT05226546

B0762021210228

Details and patient eligibility

About

Olfactory dysfunction (OD) is a well know symptom of coronavirus disease 2019 (COVID-19), accounting for 48 to 85% of patients. In 1 to 10% of cases, patients develop a chronic olfactory dysfunction (COD,) lasting more than 6 months. Recently, platelet-rich plasma (PRP) was used in patients with non-COVID-19 COD and authors reported encouraging results. In the present study, the investigators investigated the usefulness and safety of PRP injection in 56 patients with COVID-19 COD.

Our results showed that PRP in the olfactory cleft can increase the olfactory threshold one month after the injection. Moreover, our results suggest that timing of treatment may be an important factor and that PRP is a safe treatment because no adverse effects were reported throughout the study

Enrollment

56 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patient chronic olfactory dysfunction lasting more than 6 months after an infection of COVID-19

Exclusion criteria

Patient under 18 years old
Patient with blood disorder
Blood thinner user
Patient with abnormal findings on nasal endoscopy (e.g., polyposis, rhinosinusitis)